Technology

Mestastop focuses on the functional properties of primary tumour cells and uses patient primary tumour samples to identify distinct phenotypes that can act as markers of metastatic cells. Survival and progression follow-up of primary tumour patients help identify key rate-limiting steps of metastasis

Mestastop has integrated wet lab biology and machine learning algorithms, developing three proprietary platforms to unravel metastasis biology. The platforms link all discovery modalities, connecting in vitro, in vivo, and ex-vivo patient translational data.

Ninety percent of cancer deaths are due to metastasis. Still, none of the currently approved therapies focuses on delaying the process of metastasis, only delaying the primary or secondary tumour’s proliferation.

All previous targeted discovery approaches against metastasis have not been successful in clinical trials to date. The complexity of metastasis biology made identifying translatable targets challenging, impeding critical decisions in the discovery screening cascade. Further challenges of being unable to select high-risk, primary tumour patient cohorts for clinical trials decreased the feasibility of success.

Mestastop focuses on the functional properties of primary tumour cells and uses patient primary tumour samples to identify distinct phenotypes that can act as markers of metastatic cells. Survival and progression follow-up of primary tumour patients help identify key rate-limiting steps of metastasis. Mestastop has integrated wet lab biology and machine learning algorithms to develop three proprietary platforms to unravel metastasis biology. The platforms thread all discovery modalities, connecting in vitro, in vivo, and ex-vivo patient translational data.

Our Platforms

The three proprietary platforms of Mestastop dissect the complete metastasis biology into multiple phenotypic assays and help identify critically relevant steps in translational settings. Together, these platforms answer the key questions that impaired metastasis research from early discovery to clinical settings. From identifying weighted steps, novel targets and molecules, the platforms correlate in vitro biology with in vivo experimentation, all the time learning from patient samples, thereby maximizing the chances of success.

Two retrospective clinical trial studies have confirmed the efficacy of the platforms to identify potent novel anti-metastasis compounds successfully.

Prospective clinical trial studies are ongoing to develop companion diagnostics for identifying patients with higher metastasis risk which have a current accuracy greater than ninety percent.

METAssay®

Breaking Metastasis into 30 steps differentiating between moving and growing cells

METAssay®

Breaking Metastasis into 30 steps differentiating between moving and growing cells

METAssay®

Breaking Metastasis into 30 steps differentiating between moving and growing cells

METAssay®

An assay platform which separates the process of metastasis into functional steps for effective analysis.

METVivo®

High-throughput animal model for investigating metastasis allowing significantly accelerated study design and implementation.

METSCAN®

Machine learning platform for accurate identification of rate-limiting steps in metastasis, fully integrated with the in-vitro and in-vivo platforms to support accurate identification, characterization and repurposing of candidate compounds.

METAssay®

A Phenotypic Assay Platform That Dissects The Complete Metastasis Progression into Thirty Functional Steps.

Click here

METVivo®

A High-throughput and Robust Metastasis animal model Differentiating between anti-proliferative and anti-metastatic activity.

Click here

METSCAN®

Machine learning platform for accurate identification of rate-limiting steps in metastasis, fully integrated with the in-vitro and in-vivo platforms to support accurate identification, characterization and repurposing of candidate compounds.

Click here

Collaborations

Mestastop Solutions is  Partnering with various biotechs & building Unique,Translationally relevant metastasis models.

Know More

Case Studies

Refer to our case studies that answers questions like “Why node status is not a good marker of metastasis” and “why Eribulin only works for a while” and many more.
Know More

Publications

More Than Twelve International Conference Presentations and two Filed international Patents.

Know More
Reach Out To Us
Linkedin Twitter Youtube